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ABSTRACT
Objective: Our aim was to identify sub-groups of right ventricular outflow tract morphol-
ogy that would be suitable for percutaneous pulmonary valve implantation and to document
their prevalence in our patient population. Materials and Methods: Eighty-three consecutive
patients with right ventricular outflow tract dysfunction (5–41 years, 76% tetralogy of Fallot)
referred to our center for cardiovascular magnetic resonance were studied. A morphological
classification was created according to visual assessment of three-dimensional reconstructions
and detailed measurement. Diagnosis, right ventricular outflow tract type, surgical history and
treatment outcomes were documented. Results: Right ventricular outflow tract morphology
was heterogeneous; nevertheless, 5 patterns were visually identified. Type I, a pyramidal mor-
phology, was most prevalent (49%) and related to the presence of a transannular patch. Other
types (II–V) were seen more commonly in patients with conduits. Two patients had unclassi-
fiable morphology. Ninety-five percent of patients were assigned to the correct morphological
classification by visual assessment alone. Percutaneous pulmonary valve implantation was
performed successfully in 10 patients with Type II–V morphology and in 1 patient with un-
classifiable morphology. Percutaneous implantation was not performed in patients with Type I
morphology. Only right ventricular outflow tract diameters<22 mm in diameter were suitable for
the current device. Conclusions: We have created a morphological classification of the RVOT
in patients referred for assessment of RVOT dysfunction. Though only 13% of our patients
underwent percutaneous implantation, >50% of outflow tract morphologies may be suitable
for this approach, in particular with the development of new devices appropriate for larger
outflow.
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INTRODUCTION
Substantial progress in surgical techniques for repairing com-
plex congenital heart defects has resulted in increasing numbers
of patients surviving into adulthood (1). The focus has now
shifted towards treatment of morbidity, with pathology of the
pulmonary valve being one of the most common conditions that
requires intervention (2–5). However, enthusiasm for repeated
surgery is tempered by the limited longevity of surgically im-
planted valves or conduits (6). For those with obstructed out-
flow tracts, bare stenting can delay surgery but at the cost of
pulmonary regurgitation (7).
Recently, we have introduced a novel procedure that can
relieve both regurgitation and/or stenosis in the right ventric-
ular outflow tract (RVOT) by a minimally invasive approach
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(8, 9). Percutaneous pulmonary valve implantation (PPVI)
involves transcatheter placement of a valved stent within the
existing degenerated valve or conduit and can be performed
without cardiopulmonary bypass or residual pulmonary regur-
gitation. Selection of patients for this exciting new technique
depends on the presence of an appropriate site for implanta-
tion within the RVOT that will ensure device stability. The cur-
rently available device is composed of a bovine jugular venous
valve sutured into a balloon-expandable platinum-iridium stent.
It has an unexpanded length of 35 mm and can be deployed to
a maximum diameter of 22 mm. The diameter of deployment is
determined by the balloon size of the delivery system.
Cardiovascular magnetic resonance (CMR) can assess three-
dimensional (3D) morphology in patients with congenital heart
disease without exposure to x-rays (10). The aim of this study
was to identify sub-groups of RVOT morphology that would be
suitable for PPVI and to document their prevalence in our patient
population.
MATERIALS AND METHODS
Study population
We retrospectively studied 83 consecutive patients with
RVOT dysfunction, following previous repair of congenital heart
disease, who were referred to our institution for CMR between
March 2003 and February 2005. Clinical indications for PPVI
mirror the conventional criteria for surgical re-intervention and
include pulmonary regurgitation with increasing right ventricu-
lar size, substantial tricuspid regurgitation, arrhythmia and/or
impairment in exercise capacity or RVOT obstruction with
right ventricular pressure greater than 2/3 systemic. Patients
<5 years old were not included as they are currently unsuit-
able for PPVI on account of size alone. Patient characteristics
are shown in Table 1. Institutional ethical approval for CMR
was obtained and all subjects (and/or a parent/guardian) gave
informed consent for retrospective data analysis of the CMR
images.
Cardiovascular magnetic resonance
CMR was performed at 1.5T (Symphony–Maestro class,
Siemens Medical Systems, Erlangen, Germany) using a 4-
element body phased array coil. Pulmonary artery through-plane
flow data was acquired using a flow sensitive gradient echo se-
quence (TR 8ms, TE 3.8 ms, flip angle 30◦, 3 averages, parallel
imaging (iPAT) factor 2, resolution 1.3 × 1.3 × 5 mm) and
retrospective cardiac gating during free breathing. A phase cor-
rection filter was used to correct for phase errors introduced by
eddy currents and Maxwell terms. The image plane was located
at the midpoint of the pulmonary trunk (11). Pulmonary flow and
velocity was calculated from the phase contrast images using a
semi-automatic vessel edge detection algorithm with operator
correction. Regurgitant fraction was calculated as the percent
backward flow over forward flow. A 3D gradient echo sequence
was used to acquire the MR angiography after the administration
of 0.4 mL/kg of Gadolinium–imaging parameters: TR 3.7 ms,
Table 1. Patient characteristics
Category n %
Gender
Male 45 (54.2)
Female 38 (45.8)
Age at scan
5–12 years 30 (36.1)
12–18 years 38 (45.8)
>18 years 15 (18.1)
Primary diagnosis
Tetralogy of Fallot 40 (48.2)
Pulmonary atresia 19 (22.9)
Truncus arteriosus 7 (8.4)
Transposition of the great arteries 6 (7.2)
Pulmonary stenosis 5 (6.0)
Double outlet right ventricle 4 (4.8)
Other 2 (2.4)
RVOT type
Transannular patch 40 (48.2)
Homograft 23 (27.7)
Native 9 (10.8)
RVOT patch 8 (9.6)
Other 3 (3.6)
Open operations
1 67 (80.7)
2 13 (15.7)
3 2 (2.4)
4 1 (1.2)
RVOT = right ventricular outflow tract.
TE 1.4 ms, flip angle 25◦, resolution 1.3 × 0.8 × 1.3 mm. The
raw DICOM data of the patient’s MR angiogram were imported
into image processing software for 3D reconstruction.
Three-dimensional reconstruction
Reconstruction from MR images was performed using the
image processing package Mimics (Materialise Inc., Ann Arbor,
Michigan, USA). Segmentation and editing tools were used to
detect the region of interest, the RVOT, in three two-dimensional
orthogonal planes (axial, coronal and sagittal). We have previ-
ously demonstrated the accuracy of this method at our Institution
(12). When the region of interest was completely separated from
the adjacent structures, the software calculated a 3D volume of
the inner wall of the RVOT by means of pattern recognition and
interpolation algorithms (Fig. 1) (12).
Three-dimensional volume analysis
Mimics software enables rotation and scaling of 3D objects.
This allows complete appreciation of the 3D RVOT anatomy.
First, a morphological classification was created based on vi-
sualization of the patients’ RVOT alone (AMT). Five types of
RVOT morphology were identified (Fig. 2). Type I had a pyra-
midal shape (wide proximally and narrow distally). Type II had a
constant diameter. Type III had an inverted pyramidal shape (nar-
row proximally and wide distally), Type IV was wide centrally
but narrowed proximally and distally. Type V was narrowed
centrally but wide proximally and distally.
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Figure 1. Two-dimensional CMR (coronal, sagittal and axial
planes) and 3D RVOT reconstructed volume.
The center axis of the 3D RVOT volume was identified and,
starting from the pulmonary bifurcation, divided into 10 mm
segments. The RVOT volume was then sectioned by planes or-
thogonal to the center axis at each of these points. The perime-
ter of each of these sections was measured, and the shape of
the cross-sectional area standardized to a circle. During PPVI,
pressure inflation of the balloon deploying the device usually
achieves a cylindrical configuration. It is, therefore, the diame-
ter of this final circle which will influence stability of the device,
resulting in a successful procedure. The diameter of these circles
was measured and graphically represented against the length of
the RVOT, standardized in order to visualize the morphology
independent from length (Fig. 3).
Each morphological type was defined mathematically (SS).
The diameters, yA, and yC, were measured at 0% and 100%
of the RVOT length, respectively, for all morphological types.
The diameter, yB, was measured at 50% of the RVOT length
in patients with Type I, II or III morphology. In patients with
Types IV morphology, yB was measured at the point of maxi-
mum diameter irrespective of its position along the length of the
RVOT. In Type V morphology, yB was measured at the point
of minimum diameter. The average diameter y¯ along the RVOT
length was determined. The difference between diameters were
calculated and expressed as a percentage of the average RVOT
diameter.
y1 = yB − yAy¯ · 100 [1]
and
y2 = yC − yBy¯ · 100. [2]
The mathematical rules defining each morphological type are
described by the following systems and use the two unknowns
y1 and y2:
Type I :


y1 > −10%
y2 > −10%
y1 + y2 > 10% ∨ y1
> 10% ∨ y2 > 10%
[3]
Type II :


−10% ≤ y1 ≤ 10%
−10% ≤ y2 ≤ 10%
−10% ≤ y1 + y2 ≤ 10%
[4]
Type III :


y1 < 10%
y2 < 10%
y1 + y2 < −10% ∨ y1
< −10% ∨ y2 < −10%
[5]
Type IV :
{
y1 > 10%
y2 < −10% [6]
Type V :
{
y1 < −10%
y2 > 10%
· [7]
The above mathematical descriptions are graphically pre-
sented in Figure 4.
Figure 2. Five types of RVOT morphology.
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Figure 3. Mathematical volume analysis. The perimeter of each section of the RVOT is standardized to a circle. The diameter (d) of the circle is
measured and graphically represented against the length of the RVOT.
Statistical analysis
All categorical variables were expressed as an absolute num-
ber and a percentage. Comparison between categories and cal-
culation of the odds ratio were made using the Fisher’s exact
test. Significance was accepted if p < 0.05 with 95% confidence
intervals.
RESULTS
Three-dimensional volume analysis
RVOT anatomy was heterogeneous. Five common types were
identified (Fig. 2). On the basis of visual assessment, 44.6%
(37/83 patients) were assigned to type I, 16.9% (14/83) to type II,
Figure 4. Graphical representation of the systems’ solutions which mathematically describe the 5 morphological types.
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Figure 5. RVOT profiles divided by morphological types and standardized along RVOT length. Only RVOT diameters <22 mm (dashed lines)
are suitable for the current PPVI device.
3.6% (3/83) to type III, 19.3% (16/83) to type IV and 13.3%
(11/83) to type V. 2.4% (2/83) of patients could not be classified
into any of these types. However, when mathematical analysis
and standardization of length was applied (Fig. 5), 4.8% (4/83)
of patients were reclassified; 2 patients from type II and 2 from
type IV were moved to type I (Table 2). The distribution of the
classifiable patients (n = 81) in the y1y2 coordinate system
is shown in Figure 6.
Clinical correlates
The majority of patients in our population had tetralogy of
Fallot and the commonest outflow tract was a transannular patch.
The prevalence of different diagnoses and RVOT types is shown
in Table 2. No direct correlation was found between surgical his-
tory or underlying diagnosis and morphological type. Transan-
nular patch was more commonly seen in patients with type I
morphology compared to those with types II–V (Fig. 7a, Odds
Ratio 0.28, p < 0.05). Furthermore, type I morphology was as-
sociated with a higher regurgitant fraction than types II–V (Fig.
7b, Odds Ratio 0.33, p < 0.05).
Eleven patients underwent PPVI: 2 patients with type II mor-
phology, 2 with type III, 3 with type IV and 3 with type V
and 1 patient whose morphology was unclassifiable. All had
a homograft outflow tract, and none had type I morphology
which was felt unsuitable because of the risk of proximal device
dislodgement.
Twelve patients had homograft outflow tracts but did not un-
dergo PPVI. Homograft outflow tracts are often appropriate for
PPVI because of their circumferential nature and tendency to
calcify and comprise much of the clinical experience (9). Im-
portantly, however, 6 patients in this population had homograft
conduits with type I morphology and thus were unsuitable for
PPVI with the current device. These patients represent 26%
(6/23) of all those with homograft conduits in our patient popula-
tion. Three patients had insufficient valvar/conduit dysfunction
to warrant intervention to the RVOT, but all had stents placed to
treat branch pulmonary artery stenosis. Two patients underwent
surgery as PPVI was not widely available at the time of their
referral. One patient was followed-up medically as there was no
clinical indication for intervention.
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Table 2. Summary of results
Category I II III IV V Other Total
n 41 (49.4) 12 (14.5) 3 (3.6) 14 (16.9) 11 (13.3) 2 (2.4) 83
Peak velocity (m/s)
≤ 2 22 (53.7) 7 (58.3) 3 (100.0) 9 (64.3) 6 (54.5) 1 (50.0) 48
>2 and ≤3 10 (24.4) 3 (25.0) 0 (0.0) 2 (14.3) 1 (9.1) 1 (50.0) 17
>3 9 (22.0) 2 (16.7) 0 (0.0) 3 (21.4) 4 (36.4) 0 (0.0) 18
Regurgitation fraction
mild (≤20%) 7 (7.3) 4 (33.3) 2 (33.3) 3 (21.4) 6 (36.4) 1 (0.0) 23
moderate or severe (>20%) 34 (17.1) 8 (33.3) 1 (66.7) 11 (21.4) 5 (54.5) 1 (50.0) 60
Primary diagnosis
Tetralogy of Fallot 25 (61.0) 4 (33.3) 0 (0.0) 8 (57.1) 3 (27.3) 0 (0.0) 40
Pulmonary atresia 7 (17.1) 4 (33.3) 0 (0.0) 3 (21.4) 3 (27.3) 2 (100.0) 19
Truncus arteriosus 1 (2.4) 1 (8.3) 1 (33.3) 1 (7.1) 3 (27.3) 0 (0.0) 7
Transposition of the great arteries 3 (7.3) 2 (16.7) 0 (0.0) 0 (0.0) 1 (9.1) 0 (0.0) 6
Pulmonary stenosis 2 (4.9) 1 (8.3) 1 (33.3) 0 (0.0) 1 (9.1) 0 (0.0) 5
Double outlet right ventricle 2 (4.9) 0 (0.0) 0 (0.0) 2 (14.3) 0 (0.0) 0 (0.0) 4
Other 1 (2.4) 0 (0.0) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 2
RVOT type
Transannular patch 25 (61.0) 5 (41.7) 0 (0.0) 6 (42.9) 4 (36.4) 0 (0.0) 40
Homograft 6 (14.6) 4 (33.3) 2 (66.7) 4 (28.6) 6 (54.5) 1 (50.0) 23
Native 3 (7.3) 2 (16.7) 1 (33.3) 1 (7.1) 1 (9.1) 1 (50.0) 9
RVOT patch 4 (9.8) 1 (8.3) 0 (0.0) 3 (21.4) 0 (0.0) 0 (0.0) 8
Other 3 (7.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3
Procedure
Surgery 30 (73.2) 5 (41.7) 0 (0.0) 3 (21.4) 4 (36.4) 0 (0.0) 42
PPVI 0 (0.0) 2 (16.7) 2 (66.7) 3 (21.4) 3 (27.3) 1 (50.0) 11
Other percutaneous 3 (7.3) 1 (8.3) 0 (0.0) 1 (7.1) 0 (0.0) 1 (50.0) 6
Surgery + other percutaneous 1 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (9.1) 0 (0.0) 2
No intervention 7 (17.1) 4 (33.3) 1 (33.3) 7 (50.0) 3 (27.3) 0 (0.0) 22
PPVI = percutaneous pulmonary valve implantation, RVOT = right ventricular outflow tract.
DISCUSSION
This study, for the first time, characterizes the spectrum of
RVOT morphology that is present in patients late after surgi-
cal repair of congenital heart disease. Although this group often
appears heterogeneous, five common RVOT types can be de-
scribed by simple mathematical rules. Morphology of the RVOT
is a major determinant of suitability for PPVI, highlighting the
importance of 3D imaging in patient assessment and selection.
Type I morphology, a pyramidal shape, occurred in 49% of
patients. This morphology was associated with a transannular
patch repair and is unsuitable for percutaneous valve interven-
tion with the current device, as implanted prostheses would have
a high probability of migrating proximally. Importantly, some
patients with transannular patches had type II–V morphology
and may be amenable, whilst conversely a quarter of those with
homografts, who we conventionally regard as good candidates,
had unsuitable type I RVOT morphology. Whilst surgical
history can suggest suitability for PPVI, it does not, therefore,
identify adequately all patients with appropriate morphology.
Three dimensional characterization of the RVOT using CMR
or computerized tomography provides important complemen-
tary information when selecting patients for PPVI or other
minimally invasive approaches to treat RVOT dysfunction (13).
From a morphological perspective, we could have attempted
PPVI in all types of RVOT except the pyramidal type (type I). In
fact, we only performed PPVI in 11 patients from 42 with suit-
able morphologies, as other factors influence patient selection
for this procedure. The current clinical device is only suitable
for those patients whose outflow tracts are <22 mm in diam-
eter in our Institution. The development of larger devices and
new device designs that permit downsizing of dilated outflow
tracts to the size of biologically available valves is underway
and will increase the number of patients that could benefit from
a percutaneous approach in the future (13).
Further important considerations are the compliance of the
RVOT and movement of the RVOT/ pulmonary trunk junction
(e.g., due to strain in the tissues caused by attachment to the ven-
tricles), which are not assessed by CMR angiography. A patient
with type II-V morphology of <22 mm may still be unsuitable
for PPVI if the RVOT distends significantly at implantation,
as stability cannot be assured. In practice, balloon sizing, per-
formed at the time of catheterization, currently provides a 2D
assessment of distensibility that can aid decision-making. In the
future, this information could be derived non-invasively, with de-
velopment of different CMR sequences, thus avoiding catheter-
ization of patients who subsequently prove unsuitable for PPVI.
Furthermore, our experience to date suggests that stent frac-
tures are more commonly seen following PPVI in non-calcified
outflow tracts or conduits (14). Again, this may be difficult to
assess by MR angiography. Both the dynamic nature of the out-
flow tract and the wall thickness (consistent with calcification)
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Figure 6. Distribution of the classifiable patients (n = 81) in the y1 y2 coordinate system. Four datasets, corresponding to patients
who were wrongly assigned to their morphological type using visualization of 3D geometry alone, are out of their morphological type
region.
may be assessed with gradient echo cine imaging trough the
outflow tract or conduit.
Ninety-eight percent (81/83) of all morphologies could be
described according to a simple three point system. Mathemati-
cal analysis of CMR data, therefore, has allowed us to optimize
identification of the correct morphological sub-type and better
select patients for PPVI. From this work, we have developed an
algorithm that allows us to identify the morphological sub-group
from the perimeter measurements at three levels in the RVOT,
using commercially available MR software.
Type I morphology was associated with a higher pulmonary
regurgitant fraction than other morphological sub-types. The
detrimental effect of chronic pulmonary regurgitation on right
ventricular function, exercise capacity and arrhythmia potential
is well documented (2–4). Previous investigators have found a
high pulmonary regurgitant fraction to be associated with the
presence of a transannular patch (15) or a dilated pulmonary
annulus (16). We would suggest that this is likely to be a con-
sequence of the morphology of the RVOT that often develops
following placement of a transannular patch. Fluid dynamics
studies could provide an insight into the effect of different
RVOT morphologies on the generation of pulmonary regurgi-
tation and are an important area for future research. The clinical
consequences of pulmonary regurgitation and the growing avail-
ability of new transcatheter treatments, however, have already
influenced surgical approaches to primary repair. Thus, in our
institution, there is a preference for placing smaller patches and
where possible homograft conduits. It is most likely that, in the
future, there will be fewer older patients seen with type I mor-
phology and consequently a higher proportion suitable for PPVI.
Finally, although CMR is performed for all our patients re-
ferred with symptomatic RVOT dysfunction, our patient pop-
ulation may be biased. Though the exact percentages for each
morphology may differ between different institutional practices,
we believe that the 5 main morphologies we have described will
be consistent.
Patient selection for PPVI on the basis of surgical history
alone is not sufficient; 3D assessment of the RVOT with CMR
and mathematical analysis provides important additional infor-
mation. The type of morphology, in combination with RVOT
size and distensibility, allows informed selection for the cur-
rent generation of percutaneously implantable pulmonary valve
devices. Detailed knowledge of these morphologies and under-
standing of distensibility will help us to design devices in the
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Figure 7. Distribution of a) outflow tract type and b) regurgitant fraction (RF) in the 5 morphological types (n = 81 classifiable patients, %).
future that will extend the indications to this growing patient
population.
REFERENCES
1. Warnes CA, Liberthson R, Danielson GK, Dore A, Harris L, Hoff-
man JI, et al. Task force 1: The changing profile of congenital heart
disease in adult life. J Am Coll Cardiol 2001;37:1170–5.
2. Bove EL, Byrum CJ, Thomas FD, Kavey RE, Sondheimer HM,
Blackman MS, et al. The influence of pulmonary insufficiency on
ventricular function following repair of tetralogy of Fallot. Evalua-
tion using radionuclide ventriculography. J Thorac Cardiovasc Surg
1983;85:691–6.
3. Carvalho JS, Shinebourne EA, Busst C, Rigby ML, Redington
AN. Exercise capacity after complete repair of tetralogy of Fallot:
Deleterious effects of residual pulmonary regurgitation. Br Heart J
1992;67:470–3.
4. Gatzoulis MA, Balaji S, Webber SA, Sill SC, Hokanson JS, Poile
C, et al. Risk factors for arrhythmia and sudden cardiac death
late after repair of tetralogy of Fallot: A multicentre study. Lancet
2000;356:975–81.
5. Coats L, Khambadkone S, Derrick G, Sridharan S, Schievano S,
Mist B, et al. Physiological and clinical consequences of relief of
right ventricular outflow tract obstruction late after repair of con-
genital heart defects. Circulation 2006;113(17):2037–44.
6. Stark J, Bull C, Stajevic M, Jothi M, Elliott M, de Leval M. Fate of
subpulmonary homograft conduits: Determinants of late homograft
failure. J Thorac Cardiovasc Surg 1998;115(3):506–16.
7. Powell AJ, Lock JE, Keane JF, Perry SB. Prolongation of RV-PA
conduit life span by percutaneous stent implantation. Intermediate-
term results. Circulation 1995;92(11):3282–88.
8. Bonhoeffer P, Boudjemline Y, Qureshi SA, Le Bidois J, Iserin L,
Acar P, et al. Percutaneous insertion of the pulmonary valve. J Am
Coll Cardiol 2002;39(10):1664–9.
9. Khambadkone S, Coats L, Taylor A, Boudjemline Y, Derrick
G, Tsang V, et al. Percutaneous pulmonary valve implanta-
tion in humans–Results in 59 consecutive patients. Circulation
2005;112(8):1189–97.
10. Choe YH, Kim YM, Han BK, Park KG, Lee HJ. MR imaging in the
morphologic diagnosis of congenital heart disease. Radiographics
1997;17(2):403–22.
11. Taylor AM, Bogaert J. Cardiovascular MR imaging planes and seg-
mentation. In: Bogaert J, Dymarkowski S, Taylor AM, eds. Clinical
Cardiac MRI, 1st ed. Springer-Verlag, Berlin Heidelberg, 2005:85–
98.
12. Schievano S, Migliavacca F, Coats L, Khambadkone S, Carminati
M, Wilson N, et al. Planning of percutaneous pulmonary valve im-
plantation based on rapid prototyping of the right ventricular outflow
tract and pulmonary trunk from magnetic resonance imaging data.
Radiology 2007. In press.
13. Boudjemline Y, Agnoletti G, Bonnet D, Sidi D, Bonhoeffer P.
Percutaneous pulmonary valve replacement in a large right
ventricular outflow tract: an experimental study. J Am Coll Cardiol
2004;43(6):1082–7.
14. Nordmeyer J, Khambadkone S, Coats L, Schievano S, Paren-
zan G, Taylor A, et al. Analysis of stent fractures after
694 S. Schievano et al.
percutaneous pulmonary valve implantation. Circulation 2006;
114(18):II-385.
15. Davlouros PA, Kilner PJ, Hornung TS, Li W, Francis TM, Moon JC,
et al. Right ventricular function in adults with repaired tetralogy of
Fallot assessed with cardiovascular magnetic resonance imaging:
detrimental role of right ventricular outflow aneurysms or akinesia
and adverse right-to-left ventricular interaction. J Am Coll Cardiol
2002;40(11):2044–52.
16. Uebing A, Fischer G, Bethge M, Scheewe J, Schmiel F, Stieh J,
et al. Influence of the pulmonary annulus diameter on pulmonary
regurgitation and right ventricular pressure load after repair of
tetralogy of Fallot. Heart 2002;88(5):510–4.
Implications for Percutaneous Pulmonary Valve Implantation 695
